Partnering With Patient Advocacy Groups to Improve HS Awareness and Outcomes

Panelist discusses how patient advocacy groups act as critical bridges between patients, researchers, and health care providers, ultimately improving recognition, treatment, and quality of life for individuals affected by hidradenitis suppurativa.

EP: 1.Bridging the Gap in Recognizing Early Symptoms of Hidradenitis Suppurativa

EP: 2.Improving HS Diagnosis and Care Through Better Alignment of Staging and Severity

EP: 3.Addressing Social Determinants of Health in Hidradenitis Suppurativa Care

EP: 4.Economic Implications of Diagnostic Delays in Hidradenitis Suppurativa

EP: 5.Strategies for Equitable Access in Hidradenitis Suppurativa

Now Viewing

EP: 6.Partnering With Patient Advocacy Groups to Improve HS Awareness and Outcomes

Video content above is prompted by the following:

• Can you discuss the role of patient advocacy groups in promoting early recognition and comprehensive care for HS?
• Closing thoughts on HS for the AJMC viewing audience.

Related Videos

Related Content

Advertisement

January 30th 2025

Medicare Advantage Enrollees Use Less End-of-Life Home Health Care, Study Finds

Brooke McCormick

Medicare Advantage enrollees, particularly Hispanic and Asian or Pacific Islander decedents, use less end-of-life home health care than those enrolled in traditional Medicare.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

January 30th 2025

SynKIR-310 Dosing for B-NHL Begins in CELESTIAL-301 Trial

Jordyn Sava

The CELESTIAL-301 trial evaluating SynKIR-310, a novel chimeric antigen receptor T-cell therapy, has dosed its first patient with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

Published: January 29th 2025 | Updated: January 29th 2025

COVID-19 Pandemic Increased Long-Term Nursing Home Stay or Death Across All Groups

Brooke McCormick

Although long-term nursing home stay or death decreased before the COVID-19 pandemic, the trend slowed during the pandemic across all racial and ethnic groups.

January 28th 2025

Niraparib Extends PFS, Time to Next Treatment in Patients With EOC, Especially BRCA-Mutated Cases

Brooke McCormick

First-line maintenance (1LM) niraparib significantly extends progression-free survival (rwPFS) and time to next treatment (rwTTNT) in patients with epithelial ovarian cancer (EOC), with the greatest benefit observed in those considered homologous recombination-deficient (HRd) and those with BRCA-mutated (BRCAm) tumors.

Related Content

Advertisement

January 30th 2025

Medicare Advantage Enrollees Use Less End-of-Life Home Health Care, Study Finds

Brooke McCormick

Medicare Advantage enrollees, particularly Hispanic and Asian or Pacific Islander decedents, use less end-of-life home health care than those enrolled in traditional Medicare.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

January 30th 2025

SynKIR-310 Dosing for B-NHL Begins in CELESTIAL-301 Trial

Jordyn Sava

The CELESTIAL-301 trial evaluating SynKIR-310, a novel chimeric antigen receptor T-cell therapy, has dosed its first patient with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

Published: January 29th 2025 | Updated: January 29th 2025

COVID-19 Pandemic Increased Long-Term Nursing Home Stay or Death Across All Groups

Brooke McCormick

Although long-term nursing home stay or death decreased before the COVID-19 pandemic, the trend slowed during the pandemic across all racial and ethnic groups.

January 28th 2025

Niraparib Extends PFS, Time to Next Treatment in Patients With EOC, Especially BRCA-Mutated Cases

Brooke McCormick

First-line maintenance (1LM) niraparib significantly extends progression-free survival (rwPFS) and time to next treatment (rwTTNT) in patients with epithelial ovarian cancer (EOC), with the greatest benefit observed in those considered homologous recombination-deficient (HRd) and those with BRCA-mutated (BRCAm) tumors.